TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26389639
Drug: Oral-methylphenidate
Normalized name: Methylphenidan
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral-methylphenidate
Study: 18452433
Drug: Asiaticoside-containing cream
Normalized name: asiaticoside
DrugBank: Asiaticoside (DB14081)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asiaticoside-containing cream applied twice a day for 12 weeks
Study: 12713209
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (different 4-week summer day camp + monthly home Internet intervention)
Study: 7495976
Drug: Octavi S/D+heat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octavi S/D+heat treatment
Study: 6244679
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with VM 26 and CCNU once every four weeks, commencing four weeks after the completion of radiotherapy.
Study: 31732883
Drug: Combination group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination group (Fluoride then CPP-ACP, n=39)
Study: 30714336
Drug: Phaco-EX-PRESS P50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phaco-EX-PRESS P50 with mitomycin C (0.2 mg/ml for 2 min)
Study: 30714336
Drug: Phaco-NPDS with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phaco-NPDS with Esnoper V2000 and mitomycin C (0.2 mg/ml for 2 min)
Study: 26003782
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and clopidogrel 75mg/d
Study: 23093541
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg prednisone over 5 days
Study: 21641867
Drug: Continuous oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Continuous oxaliplatin and fluoropyrimidine combination chemotherapy (arm A)
Study: 21641867
Drug: Intermittent chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent chemotherapy (arm C)
Study: 21641867
Drug: Continuous chemotherapy
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous chemotherapy (arm A)
Study: 9493662
Drug: Cathepsin G-like
Normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cathepsin G-like activities
Study: 3594105
Drug: Papaverine and
Normalized name: Papaverine and derivatives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Papaverine and phentolamine (30 mg papaverine and 1 mg phentolamine, 2 ml injection)
Study: 3594105
Drug: Saline (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (2 ml injection)
Study: 31793041
Drug: MAL-photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAL-photodynamic therapy (MAL-PDT)
Study: 31793041
Drug: ingenol mebutate
Normalized name: Ingenol Mebutate
DrugBank: Ingenol mebutate (DB05013)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ingenol mebutate gel (IMB)
Study: 31793041
Drug: diclofenac plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: diclofenac plus hyaluronate gel (DHA)
Study: 29689257
Drug: Diphenhydramine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine (50 mg IV)
Study: 23632672
Drug: Local infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local infiltration analgesia with peri-articular injection of bupivacaine, morphine, and methylprednisolone.
Study: 12859221
Drug: Sequential high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential high dose chemotherapy (HDC) with granulocyte colony-stimulating factor (filgrastim) and stem cell support
Study: 9001371
Drug: DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA supplementation (1.62 g/d)
Study: 1309944
Drug: Continuous estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous estradiol valerate (2 mg) plus cyproterone acetate (1 mg)
Study: 1309944
Drug: Sequential estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential estradiol valerate (2 mg) plus levonorgestrel (75 micrograms)
Study: 6734703
Drug: Theolin Retard
Normalized name: diclofenac sodium Extended Release Oral Tablet [Lofensaid Retard]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theolin Retard 300 mg (sustained release tablet)
Study: 6734703
Drug: Intravenous aminophylline
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous aminophylline (reference material)
Study: 30955455
Drug: 3 mg.kg-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg.kg-1 caffeine (CAF3)
Study: 30955455
Drug: 6 mg.kg-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg.kg-1 caffeine (CAF6)
Study: 27293053
Drug: Single intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intramuscular injection of bone marrow mononuclear cells (n = 11)
Study: 27293053
Drug: Four intramuscular
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four intramuscular injections of bone marrow mononuclear cells (n = 11)
Study: 27293053
Drug: Both single
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both single and four injections of bone marrow mononuclear cells
Study: 19576318
Drug: Eptifibatide plus
Normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eptifibatide plus a heparin product
Study: 18277670
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (1 g in 250 ml normal saline, infused before tourniquet deflation and again 3 hours later)
Study: 18277670
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (250 ml infused intravenously)
Study: 15277964
Drug: Rehabilitation (physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehabilitation (physical and occupational therapy sessions five times per week for 24.8 +/- 8.1 days)
Study: 9807208
Drug: Intensive preoperative
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive preoperative radiotherapy (IPRT) combined with postoperative chemo- and hormonal therapy
Study: 7815697
Drug: Continuous interpleural
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous interpleural infusion of 0.5% bupivacaine at the rate of 5 ml.h‐1
Study: 7815697
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural infusion of 0.25% bupivacaine and 0.025 buprenorphine at the rate of 1 ml.h‐1
Study: 31112383
Drug: Cisatracurium continuous
Normalized name: Cisatracurium
DrugBank: Cisatracurium (DB00565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisatracurium continuous infusion (median duration 47.8 hours, median dose 1807 mg) with deep sedation
Study: 31112383
Drug: Cisatracurium continuous
Normalized name: Cisatracurium
DrugBank: Cisatracurium (DB00565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisatracurium continuous infusion
Study: 28492492
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein supplement (PRO)
Study: 28492492
Drug: Maltodextrin supplement
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltodextrin supplement (CHO)
Study: 21967071
Drug: Nalmefene 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalmefene 80 mg/day
Study: 23910665
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg on day 7
Study: 19267709
Drug: Metformin 1
Normalized name: metformin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1 g x two times daily
Study: 19267709
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir before bedtime
Study: 19267709
Drug: Biphasic insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biphasic insulin aspart 30 before dinner
Study: 19267709
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart before main meals and insulin detemir before bedtime
Study: 11730741
Drug: Luteal phase
Normalized name: Nuphar lutea leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luteal phase support with vaginal progesterone beginning on day 6 after oocyte retrieval (GnRH agonist group)
Study: 11730741
Drug: Luteal phase
Normalized name: Nuphar lutea leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luteal phase support with vaginal progesterone beginning on day 3 after oocyte retrieval (GnRH agonist group)
Study: 3303278
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate aerosol 400 micrograms once daily
Study: 3303278
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate aerosol 200 micrograms twice daily
Study: 22882572
Drug: Same-day discharge
Normalized name: SAMe
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same-day discharge with remote monitoring for 24 hours after ICD implant
Study: 12383667
Drug: Azithromycin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (250 mg daily for bodyweight ≤40 kg; 500 mg daily for bodyweight >40 kg)
Study: 12840867
Drug: Theophylline (Protheo,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (Protheo, 400 mg, qd)
Study: 8772970
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulphate 2 gm bolus
Study: 8772970
Drug: Intravenous verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous verapamil 5 mg
Study: 6259922
Drug: Liquid glucose
Normalized name: Liquid glucose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid glucose formula (75 g carbohydrate)
Study: 6259922
Drug: Brown rice
Normalized name: Brown rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brown rice (75 g carbohydrate)
Study: 6259922
Drug: Pinto beans
Normalized name: Bean
DrugBank: Bean (DB14709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinto beans (75 g carbohydrate)
Study: 6259922
Drug: All Bran
Normalized name: All bran loaf
Approvals — FDA: no, EMA: no, PMDA: no
Description: All Bran (75 g carbohydrate)
Study: 31653011
Drug: Dietary supplement
Normalized name: dietary supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplement plus physical activity
Study: 24660837
Drug: Parenteral n‐3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral n‐3 fatty acids (2 ml/kg/day of a lipid emulsion containing highly refined fish oil for 7 days)
Study: 24660837
Drug: Parenteral n‐3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral n‐3 fatty acids
Study: 19083199
Drug: Synbiotic 2000
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synbiotic 2000 FORTE (twice a day)
Study: 17720993
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose Urocortin 2 (25 microg)
Study: 17720993
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose Urocortin 2 (100 microg)
Study: 16633764
Drug: Preoperative flurbiprofen
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative flurbiprofen axetil, 1 mg x kg(‐1)
Study: 14514944
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (ACBT)
Study: 10789839
Drug: Tacalcitol 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacalcitol 0.4 microg/g ointment
Study: 10789839
Drug: Tacalcitol 4
Normalized name: Tacalcitol 4 microgram/g cutaneous ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacalcitol 4 microg/g ointment
Study: 10789839
Drug: Tacalcitol 40
Normalized name: tacalcitol
DrugBank: Tacalcitol (DB13689)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacalcitol 40 microg/g ointment
Study: 8695107
Drug: Intrathecal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal fentanyl 25 micrograms administered through a spinal needle
Study: 8695107
Drug: No intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intravenous (i.v.) fluid
Study: 1832500
Drug: AM3 (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: AM3 (a new oral biological response modifier)
Study: 1832500
Drug: Oral washes
Normalized name: Zencia Wash
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral washes (control group)
Study: 6350411
Drug: Nifedipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10 mg single dose)
Study: 6350411
Drug: Nifedipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10 mg t.i.d. for 4 days)
Study: 6350411
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (4 days)
Study: 26681392
Drug: Ranibizumab or
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab or Bevacizumab (anti-VEGF drugs)
Study: 19160408
Drug: Two applications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two applications of Mitomycin-C (MMC) (0.5 mg/mL)
Study: 19160408
Drug: One application
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One application of Mitomycin-C (MMC) (0.5 mg/mL)
Study: 16385651
Drug: Thiopental (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental (2 mL, 50 mg)
Study: 20581776
Drug: Saline (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (2 mL)
Study: 10543285
Drug: SR 27417A
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR 27417A (20 mg, orally)
Study: 2182288
Drug: Mifepristone (longer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (longer treatment)
Study: 7404090
Drug: Prolonged glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Prolonged glucagon infusion
Study: 27806191
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg acebilustat
Study: 27806191
Drug: Acebilustat (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebilustat (50 mg and 100 mg)
Study: 24057341
Drug: Tirofiban maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirofiban maintenance infusion for 24 hours
Study: 24057341
Drug: Tirofiban maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirofiban maintenance infusion for 48 hours
Study: 21477940
Drug: Concurrent carboplatin/paclitaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent carboplatin/paclitaxel with 74 Gy 3D-CRT
Study: 21477940
Drug: Concurrent gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent gemcitabine with 74 Gy 3D-CRT
Study: 21477940
Drug: Treatment-related pulmonary
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-related pulmonary toxicity
Study: 19039248
Drug: Carboplatin AUC
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC 5 plus PLD 30 mg/m(2) every 3 weeks for 6 cycles
Study: 19039248
Drug: Carboplatin AUC
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC 5 plus paclitaxel 175 mg/m(2) every 3 weeks for 6 cycles
Study: 17460368
Drug: Metformin 500-750
Normalized name: metformin hydrochloride 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 500-750 mg/day
Study: 9684138
Drug: Postoperative transarterial
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative transarterial infusion chemotherapy (PTIC)
Study: 7889228
Drug: Crossover designs
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Crossover designs with three or more treatment periods
Study: 7889228
Drug: Interposing sufficiently
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interposing sufficiently long 'washout' periods between successive treatments
Study: 18091334
Drug: Postoperative radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative radiotherapy plus carboplatin 100 mg/m intravenously once weekly during radiation (arm B)
Study: 14533615
Drug: Ezetimibe alone
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe alone or added to existing statin therapy
Study: 14618039
Drug: Concomitant beta-blocker
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant beta-blocker use
Study: 25665612
Drug: Xuebijing injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuebijing injection (50 mL added with 100 mL of 0.9% sodium chloride injection, twice a day for 5 days)
Study: 22951334
Drug: Involuntary medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Involuntary medication as the first choice intervention
Study: 22951334
Drug: Involuntary medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Involuntary medication
Study: 9595926
Drug: SQA (quaternary
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQA (quaternary ammonium antimicrobial compounds)
Study: 9595926
Drug: CL (clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CL (clindamycin 2% intravaginal cream)
Study: 23815103
Drug: BDP nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP nasal aerosol 320 µg/day
Study: 23815103
Drug: BDP nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP nasal aerosol 80 µg and 160 µg
Study: 21829138
Drug: rcp45 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rcp45 vaccine (2 intranasal doses administered 4 to 10 weeks apart)
Study: 21829138
Drug: rcp45 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rcp45 vaccine (2nd dose)
Study: 21829138
Drug: cp45 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cp45 vaccine (biologically derived)
Study: 21829138
Drug: rcp45 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rcp45 vaccine
Study: 19468225
Drug: Ivabradine 5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivabradine 5, 7.5, or 10 mg b.i.d. for 3 or 4 months
Study: 14757687
Drug: Insulin at
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin at 2.5 U/h
Study: 9395153
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cognitive-behaviour therapy with a serotonergic antidepressant (fluvoxamine)
Study: 9395153
Drug: Non-responders at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-responders at post-treatment
Study: 9395153
Drug: Severity of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severity of symptoms, motivation for treatment, and dimensional score on the PDQ-R for cluster A personality disorder
Study: 8187446
Drug: Oral gold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral gold (6-9 mg auranofin by mouth daily)
Study: 8187446
Drug: Injectable gold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable gold (Solganal, aurothioglucose, 50-100 mg, intramuscularly, 2 to 4 weeks)
Study: 3025306
Drug: IgG and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgG and IgM antibody reactivity
Study: 29145626
Drug: Tobacco Treatment
Normalized name: Tobacco
DrugBank: Tobacco leaf (DB10710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobacco Treatment Advocates (TTAs) intervention with multiple visits, motivational interviewing, cessation counseling, and navigation to cessation resources
Study: 29145626
Drug: Tobacco Treatment
Normalized name: Tobacco
DrugBank: Tobacco leaf (DB10710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobacco Treatment Advocates (TTAs) intervention
Study: 28158212
Drug: nCPAP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: nCPAP therapy for more than four hours per night, for more than 70% of nights
Study: 28158212
Drug: nCPAP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: nCPAP therapy (entire group)
Study: 21565487
Drug: Celecoxib 400mg
Normalized name: CELECOXIB 400MG CAP
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib 400mg b.i.d. in addition to palliative chemotherapy
Study: 21565487
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in addition to palliative chemotherapy
Study: 17975234
Drug: Control (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (normal saline 2 mL i.v.)
Study: 15916166
Drug: 400 mg/d
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/d vitamin E and 1000 mg/d vitamin C for 30 days
Study: 9690396
Drug: Initial 100‐microg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial 100‐microg intravenous bolus followed by a continuous 25 microg/hr octreotide infusion (group I)
Study: 9690396
Drug: Continuous 25
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous 25 microg/hr octreotide infusion without an initial bolus (group II)
Study: 9690396
Drug: Continuous placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous placebo infusion (group III)
Study: 2478049
Drug: PCA with
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA with morphine (1.8 mg, n = 16)
Study: 2478049
Drug: PCA with
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA with oxymorphone (0.3 mg, n = 16)
Study: 2478049
Drug: PCA +
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA + BI with morphine (0.6 mg/hour, n = 16)